RESUMEN
No disponible
Asunto(s)
Humanos , Digoxina/uso terapéutico , Guías de Práctica Clínica como Asunto , Digoxina/toxicidad , Atención Ambulatoria/métodos , Digoxina/farmacocinéticaAsunto(s)
Angiotensinógeno , Diabetes Mellitus Tipo 2 , Albuminuria , Glucosa , Humanos , Hipoglucemiantes , SodioRESUMEN
Radiotherapy, an essential component of cancer treatment, is not without risk to bone, particularly to the immature or growing skeleton. Known side effects range from post-radiation osteitis to osteoradionecrosis. We report the case of a 14-year-old male patient undergoing denosumab treatment, a new antiresorptive agent, for osteoradionecrosis. The patient exhibited fractures and associated pain and functional limitations secondary to radiation for the treatment of an embryonal rhabdomyosarcoma of prostate grade III administered at age 5 years. After treatment with denosumab, the pain disappeared, bone remodeling markers dramatically declined, bone mass increased, and pathological bone scan findings resolved without adverse effects or new fractures.
Asunto(s)
Denosumab/administración & dosificación , Fracturas Óseas/tratamiento farmacológico , Osteorradionecrosis/tratamiento farmacológico , Adolescente , Biomarcadores/sangre , Remodelación Ósea/efectos de los fármacos , Fracturas Óseas/sangre , Fracturas Óseas/diagnóstico por imagen , Fracturas Óseas/etiología , Humanos , Masculino , Osteorradionecrosis/sangre , Osteorradionecrosis/diagnóstico por imagen , Osteorradionecrosis/etiología , Radiografía , Radioterapia/efectos adversos , Rabdomiosarcoma Embrionario/diagnóstico por imagen , Rabdomiosarcoma Embrionario/radioterapiaRESUMEN
BACKGROUND: A prospective study was performed to compare the prevalence of morphometric vertebral fractures (MVF) between patients with inflammatory bowel disease (IBD) and healthy subjects and to identify predictive factors of fracture. METHODS: A total of 107 patients with IBD (53 with Crohn's disease and 54 with ulcerative colitis) and 51 healthy subjects participated in the study. Information about anthropometric parameters, toxins, previous fractures, and parameters related to this disease were evaluated. The index of vertebral deformity, bone mass density (BMD), and biochemical parameters were calculated. RESULTS: A total of 72 fractures were detected in 38.32% of patients with IBD, and 10 fractures were detected in 13.73% of healthy subjects; the risk of fracture in patients with IBD was higher than that in control subjects (OR, 4.03; 95% CI, 1.652-9.847; p < 0.002). We found no correlation between fracture and BMD in patients with IBD (lumbar spine, r = -0.103, p = 0.17 and femoral neck, r = -0.138, p = 0.07). Corticosteroid treatment was not associated with prevalent vertebral fractures nor with taking corticosteroids (r = 0.135, p = 0.14) or the duration for which they were taken (r = 0.08, p = 0.38), whereas this relationship was present in the controls (r = -0.365, p = 0.01). In the multivariate analysis, none of the measured parameters were significantly predictive of fracture, only to manifested IBD. Hypovitaminosis D was observed in 55.14% of patients with IBD. CONCLUSIONS: The prevalence of morphometric vertebral fractures is higher in patients with IBD than in the healthy population, without association with BMD or corticoid treatment. Simply having IBD was proven to be a predictive factor of fracture. We observed a high incidence of hypovitaminosis D in patients with IBD.
